{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:40:59Z","timestamp":1773286859203,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2020T130022ZX"],"award-info":[{"award-number":["2020T130022ZX"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to a significant number of mortalities worldwide. COVID-19 poses a serious threat to human life. The clinical manifestations of COVID-19 are diverse and severe and 20% of infected patients are reported to be in a critical condition. A loss in lung function and pulmonary fibrosis are the main manifestations of patients with the severe form of the disease. The lung function is affected, even after recovery, thereby greatly affecting the psychology and well-being of patients, and significantly reducing their quality of life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants must meet the following simultaneous inclusion criteria: over 18\u00a0years of age, should have recovered from severe or critical COVID-19 cases, should exhibit pulmonary fibrosis after recovery, and should exhibit Qi-Yin deficiency syndrome as indicated in the system of traditional Chinese medicine (TCM). The eligible candidates will be randomized into treatment or control groups. The treatment group will receive modern medicine (pirfenidone) plus TCM whereas the control group will be administered modern medicine plus TCM placebo. The lung function index will be continuously surveyed and recorded. By comparing the treatment effect between the two groups, the study intend to explore whether TCM can improve the effectiveness of modern medicine in patients with pulmonary fibrosis arising as a sequelae after SARS-CoV-2 infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Pulmonary fibrosis is one of fatal sequelae for some severe or critical COVID-19 cases, some studies reveal that pirfenidone lead to a delay in the decline of forced expiratory vital capacity, thereby reducing the mortality partly. Additionally, although TCM has been proven to be efficacious in treating pulmonary fibrosis, its role in treating pulmonary fibrosis related COVID-19 has not been explored. Hence, a multicenter, parallel-group, randomized controlled, interventional, prospective clinical trial has been designed and will be conducted to determine if a new comprehensive treatment for pulmonary fibrosis related to COVID-19 is feasible and if it can improve the quality of life of patients.<\/jats:p>\n                <jats:p><jats:italic>Trial registration:<\/jats:italic> This multicenter, parallel-group, randomized controlled, interventional, prospective trial was registered at the Chinese Clinical Trial Registry (ChiCTR2000033284) on 26th May 2020 (prospective registered). \n                      <\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40249-021-00813-8","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T02:02:33Z","timestamp":1616032953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial"],"prefix":"10.1186","volume":"10","author":[{"given":"Zhen-Hui","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gai-Ge","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Xu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Guang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Yong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8929-4433","authenticated-orcid":false,"given":"Shun-Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"issue":"4","key":"813_CR1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses","year":"2020","unstructured":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536\u201344. https:\/\/doi.org\/10.1038\/s41564-020-0695-z.","journal-title":"Nat Microbiol."},{"issue":"5","key":"813_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41564-020-0713-1","volume":"5","author":"WH Kong","year":"2020","unstructured":"Kong WH, Li Y, Peng MW, Kong DG, Yang XB, Wang L, et al. SARS-CoV-2 detection in patients with influenza-like illness. Nat Microbiol. 2020;5(5):675\u20138. https:\/\/doi.org\/10.1038\/s41564-020-0713-1.","journal-title":"Nat Microbiol"},{"issue":"1","key":"813_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40249-020-00683-6","volume":"9","author":"H Wan","year":"2020","unstructured":"Wan H, Cui JA, Yang GJ. Risk estimation and prediction of the transmission of coronavirus disease-2019 (COVID-19) in the mainland of China excluding Hubei province. Infect Dis Poverty. 2020;9(1):116. https:\/\/doi.org\/10.1186\/s40249-020-00683-6.","journal-title":"Infect Dis Poverty"},{"issue":"18","key":"813_CR4","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1908681.","journal-title":"N Engl J Med"},{"issue":"10224","key":"813_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(20)30251-8.","journal-title":"Lancet"},{"issue":"8","key":"813_CR6","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782\u201393. https:\/\/doi.org\/10.1001\/jama.2020.12839.","journal-title":"JAMA"},{"issue":"2","key":"813_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3760\/cma.j.issn.0254-6450.2020.02.003","volume":"41","author":"Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention","year":"2020","unstructured":"Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145\u201351. https:\/\/doi.org\/10.3760\/cma.j.issn.0254-6450.2020.02.003 (In Chinese).","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"issue":"13","key":"813_CR8","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa2001316.","journal-title":"N Engl J Med"},{"issue":"22","key":"813_CR9","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1056\/NEJMoa2008457","volume":"382","author":"MM Arons","year":"2020","unstructured":"Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382(22):2081\u201390. https:\/\/doi.org\/10.1056\/NEJMoa2008457.","journal-title":"N Engl J Med"},{"issue":"1","key":"813_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40249-020-00781-5","volume":"9","author":"LS Deng","year":"2020","unstructured":"Deng LS, Yuan J, Ding L, Chen YL, Zhao CH, Chen GQ, et al. Comparison of patients hospitalized with COVID-19, H7N9 and H1N1. Infect Dis Poverty. 2020;9(1):163. https:\/\/doi.org\/10.1186\/s40249-020-00781-5.","journal-title":"Infect Dis Poverty"},{"issue":"7821","key":"813_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/d41586-020-02360-y","volume":"584","author":"H Ledford","year":"2020","unstructured":"Ledford H. Antibody therapies could be a bridge to a coronavirus vaccine\u2014but will the world benefit? Nature. 2020;584(7821):333\u20134. https:\/\/doi.org\/10.1038\/d41586-020-02360-y.","journal-title":"Nature"},{"issue":"5","key":"813_CR12","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2020.10044","volume":"324","author":"L Li","year":"2020","unstructured":"Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460\u201370. https:\/\/doi.org\/10.1001\/jama.2020.10044.","journal-title":"JAMA"},{"issue":"1","key":"813_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14","author":"H Lu","year":"2020","unstructured":"Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69\u201371. https:\/\/doi.org\/10.5582\/bst.2020.01020.","journal-title":"Biosci Trends"},{"issue":"13","key":"813_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2020.17022","volume":"324","author":"DC Angus","year":"2020","unstructured":"Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317\u201329. https:\/\/doi.org\/10.1001\/jama.2020.17022.","journal-title":"JAMA"},{"issue":"11","key":"813_CR15","doi-asserted-by":"publisher","first-page":"e689","DOI":"10.1016\/S2665-9913(20)30305-2","volume":"2","author":"CA Gentry","year":"2020","unstructured":"Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, Williams RJ 2nd. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheumatol. 2020;2(11):e689\u201397. https:\/\/doi.org\/10.1016\/S2665-9913(20)30305-2.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"813_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa2016638","volume":"383","author":"DR Boulware","year":"2020","unstructured":"Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2016638.","journal-title":"N Engl J Med"},{"issue":"2","key":"813_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.micinf.2020.01.004","volume":"22","author":"J Chen","year":"2020","unstructured":"Chen J. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect. 2020;22(2):69\u201371. https:\/\/doi.org\/10.1016\/j.micinf.2020.01.004.","journal-title":"Microbes Infect"},{"key":"813_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42399-020-00487-7","volume":"27","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Pelliccia C, Ferrara F. COVID-19 patients with pulmonary fibrotic tissue: clinical pharmacological rational of antifibrotic therapy. SN Compr Clin Med. 2020;27:1\u20134. https:\/\/doi.org\/10.1007\/s42399-020-00487-7.","journal-title":"SN Compr Clin Med"},{"key":"813_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206879","author":"HF Schwensen","year":"2020","unstructured":"Schwensen HF, Borreschmidt LK, Storgaard M, Redsted S, Christensen S, Madsen LB. Fatal pulmonary fibrosis: a post-COVID-19 autopsy case. J Clin Pathol. 2020. https:\/\/doi.org\/10.1136\/jclinpath-2020-206879.","journal-title":"J Clin Pathol."},{"issue":"10239","key":"813_CR20","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","volume":"395","author":"MJ Cummings","year":"2020","unstructured":"Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(20)31189-2.","journal-title":"Lancet"},{"issue":"8","key":"813_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","volume":"8","author":"PM George","year":"2020","unstructured":"George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807\u201315. https:\/\/doi.org\/10.1016\/S2213-2600(20)30225-3.","journal-title":"Lancet Respir Med"},{"issue":"2020","key":"813_CR22","doi-asserted-by":"publisher","first-page":"6175964","DOI":"10.1155\/2020\/6175964","volume":"10","author":"AS Ojo","year":"2020","unstructured":"Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med. 2020;10(2020):6175964. https:\/\/doi.org\/10.1155\/2020\/6175964.","journal-title":"Pulm Med"},{"issue":"2","key":"813_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","volume":"8","author":"TM Maher","year":"2020","unstructured":"Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147\u201357. https:\/\/doi.org\/10.1016\/S2213-2600(19)30341-8.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"813_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13643-020-01343-4","volume":"9","author":"Y Li","year":"2020","unstructured":"Li Y, Liu X, Guo L, Li J, Zhong D, Zhang Y, et al. Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis. Syst Rev. 2020;9(1):75. https:\/\/doi.org\/10.1186\/s13643-020-01343-4.","journal-title":"Syst Rev"},{"issue":"39","key":"813_CR25","doi-asserted-by":"publisher","first-page":"e22396","DOI":"10.1097\/MD.0000000000022396","volume":"99","author":"HY Zhang","year":"2020","unstructured":"Zhang HY, Pang LJ, Lv XD, Liu C, Nan MH. Multiple Traditional Chinese Medicine interventions for idiopathic pulmonary fibrosis: a protocol for systematic review and meta-analysis of overview. Medicine (Baltimore). 2020;99(39):e22396. https:\/\/doi.org\/10.1097\/MD.0000000000022396.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"813_CR26","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3389\/fphar.2020.01066","volume":"17","author":"N Liang","year":"2020","unstructured":"Liang N, Ma Y, Wang J, Li H, Wang X, Jiao L, et al. Chinese patent medicines in the treatment of coronavirus disease 2019 (COVID-19) in China. Front Pharmacol. 2020;17(11):1066. https:\/\/doi.org\/10.3389\/fphar.2020.01066.","journal-title":"Front Pharmacol"},{"issue":"10","key":"813_CR27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s11655-017-2429-5","volume":"25","author":"Q Wu","year":"2019","unstructured":"Wu Q, Zhou Y, Feng FC, Zhou XM. Effectiveness and safety of chinese medicine for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chin J Integr Med. 2019;25(10):778\u201384. https:\/\/doi.org\/10.1007\/s11655-017-2429-5.","journal-title":"Chin J Integr Med"},{"issue":"2020","key":"813_CR28","doi-asserted-by":"publisher","first-page":"1752387","DOI":"10.1155\/2020\/1752387","volume":"12","author":"K Ji","year":"2020","unstructured":"Ji K, Ma J, Wang L, Li N, Dong S, Shi L. Efficacy and safety of traditional Chinese medicine in idiopathic pulmonary fibrosis: a meta-analysis. Evid Based Complement Alternat Med. 2020;12(2020):1752387. https:\/\/doi.org\/10.1155\/2020\/1752387.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"09","key":"813_CR29","first-page":"1269","volume":"29","author":"GC Zhang","year":"2014","unstructured":"Zhang GC, Lin M, Le J, Qiu Z, Zhou X. Clinical research of huqi huoxue decoction in treating idiopathic pulmonary fibrosis. China J Chin Med . 2014;29(09):1269\u201370 (In Chinese).","journal-title":"China J Chin Med"},{"issue":"01","key":"813_CR30","first-page":"44","volume":"26","author":"HH Xue","year":"2020","unstructured":"Xue HH, Zhang HY, Fu JY, Sun S, Lu ZH, Lu CH. Clinical study of huaxian decoction in treating idiopathic pulmonary fibrosis combined with qi and yin deficiency and intermingled phlegm-blood stas. Geriatr Health Care. 2020;26(01):44\u20137 (In Chinese).","journal-title":"Geriatr Health Care"},{"issue":"1","key":"813_CR31","first-page":"51","volume":"1","author":"B Zhong","year":"2009","unstructured":"Zhong B. How to calculate sample size in randomized controlled trial? J Thorac Dis. 2009;1(1):51\u20134.","journal-title":"J Thorac Dis"},{"issue":"20","key":"813_CR32","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.19540\/j.cnki.cjcmm.20200229.501","volume":"45","author":"MA Lian","year":"2020","unstructured":"Lian MA, Ke-Bin W, Sheng-Xian WU. Research and development of new traditional Chinese medicine drugs for certain syndromes based on \u201ctheoretical innovation.\u201d Zhongguo Zhong Yao Za Zhi. 2020;45(20):5048\u201356. https:\/\/doi.org\/10.19540\/j.cnki.cjcmm.20200229.501 (In Chinese).","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"issue":"04","key":"813_CR33","first-page":"252","volume":"31","author":"MR Fang","year":"2012","unstructured":"Fang MR, Han KH, Wang SC. The clinical study on TCM syndrome for idiopathic pulmonary fibrosis. Beijing J Trad Chin Med . 2012;31(04):252\u20133 (In Chinese).","journal-title":"Beijing J Trad Chin Med"},{"issue":"8","key":"813_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/jcm7080201","volume":"7","author":"SL Barratt","year":"2018","unstructured":"Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic pulmonary fibrosis (IPF): an overview. J Clin Med. 2018;7(8):201. https:\/\/doi.org\/10.3390\/jcm7080201.","journal-title":"J Clin Med"},{"issue":"8","key":"813_CR35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMc1807508","volume":"379","author":"V Poletti","year":"2018","unstructured":"Poletti V, Tomassetti S, Ravaglia C. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;379(8):797. https:\/\/doi.org\/10.1056\/NEJMc1807508.","journal-title":"N Engl J Med"},{"issue":"9","key":"813_CR36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1164\/rccm.201907-1324ED","volume":"200","author":"G Raghu","year":"2019","unstructured":"Raghu G, Remy-Jardin M, Myers J, Richeldi L, Wilson KC. The 2018 diagnosis of idiopathic pulmonary fibrosis guidelines: surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory. Am J Respir Crit Care Med. 2019;200(9):1089\u201392. https:\/\/doi.org\/10.1164\/rccm.201907-1324ED.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"813_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40249-020-00660-z","volume":"9","author":"SY Zhang","year":"2020","unstructured":"Zhang SY, Fu JY, Guo XY, Wu DZ, Zhang T, Li C, et al. Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen. Infect Dis Poverty. 2020;9(1):50. https:\/\/doi.org\/10.1186\/s40249-020-00660-z.","journal-title":"Infect Dis Poverty"},{"issue":"11","key":"813_CR38","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3389\/fimmu.2020.01022","volume":"12","author":"Y Liang","year":"2020","unstructured":"Liang Y, Wang ML, Chien CS, et al. Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV, and SARS-CoV-2 infection. Front Immunol. 2020;12(11):1022. https:\/\/doi.org\/10.3389\/fimmu.2020.01022.","journal-title":"Front Immunol"},{"issue":"11","key":"813_CR39","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S2213-2600(20)30415-X","volume":"8","author":"A Schultze","year":"2020","unstructured":"Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8(11):1106\u201320. https:\/\/doi.org\/10.1016\/S2213-2600(20)30415-X.","journal-title":"Lancet Respir Med"},{"key":"813_CR40","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.biopha.2017.07.124","volume":"94","author":"S Beigh","year":"2017","unstructured":"Beigh S, Rashid H, Sharma S, Parvez S, Raisuddin S. Bleomycin-induced pulmonary toxicopathological changes in rats and its prevention by walnut extract. Biomed Pharmacother. 2017;94:418\u201329. https:\/\/doi.org\/10.1016\/j.biopha.2017.07.124.","journal-title":"Biomed Pharmacother"},{"key":"813_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.intimp.2017.03.020","volume":"47","author":"L Tao","year":"2017","unstructured":"Tao L, Cao J, Wei W, Xie H, Zhang M, Zhang C. Protective role of rhapontin in experimental pulmonary fibrosis in vitro and in vivo. Int Immunopharmacol. 2017;47:38\u201346. https:\/\/doi.org\/10.1016\/j.intimp.2017.03.020.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"813_CR42","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.3892\/mmr.2015.3333","volume":"11","author":"H He","year":"2015","unstructured":"He H, Tang H, Gao L, Wu Y, Feng Z, Lin H, Wu T. Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis in rats. Mol Med Rep. 2015;11(6):4190\u20136. https:\/\/doi.org\/10.3892\/mmr.2015.3333.","journal-title":"Mol Med Rep"},{"issue":"8","key":"813_CR43","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/ptr.5120","volume":"28","author":"GX Lu","year":"2014","unstructured":"Lu GX, Bian DF, Ji Y, Guo JM, Wei ZF, Jiang SD, et al. Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice by downregulating collagen deposition. Phytother Res. 2014;28(8):1224\u201331. https:\/\/doi.org\/10.1002\/ptr.5120.","journal-title":"Phytother Res"},{"issue":"07","key":"813_CR44","first-page":"11","volume":"26","author":"HH Xue","year":"2020","unstructured":"Xue HH, Lu ZH, Lu CH, Sun S, Zhang HY. Effection of huaxian decoction lyophilized powder solution on proliferation and differentiation of human embryonic lung fibroblasts induced by tGF-\u03b21. Guiding J Trad Chin Med Pharmacol. 2020;26(07):11\u20135 ((In Chinese)).","journal-title":"Guiding J Trad Chin Med Pharmacol"},{"issue":"5","key":"813_CR45","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3390\/jcm9051583","volume":"9","author":"L Ang","year":"2020","unstructured":"Ang L, Song E, Lee HW, Lee MS. Herbal medicine for the treatment of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2020;9(5):1583. https:\/\/doi.org\/10.3390\/jcm9051583.","journal-title":"J Clin Med"},{"issue":"9","key":"813_CR46","doi-asserted-by":"publisher","first-page":"e0238828","DOI":"10.1371\/journal.pone.0238828","volume":"15","author":"M Zeng","year":"2020","unstructured":"Zeng M, Li L, Wu Z. Traditional Chinese medicine Lianhua Qingwen treating corna virus disease 2019(COVID-19): meta-analysis of randomized controlled trials. PLoS ONE. 2020;15(9):e0238828. https:\/\/doi.org\/10.1371\/journal.pone.0238828.","journal-title":"PLoS ONE"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-021-00813-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-021-00813-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-021-00813-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:37:59Z","timestamp":1628617079000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-021-00813-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1186\/s40249-021-00813-8","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Guangzhou Women and Children\u2019s Medical Center(No. 202028500) and the Chinese Clinical Trial Registry (ChiCTR2000033284).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}